267 related articles for article (PubMed ID: 29143898)
1. The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma.
Parekh HD; Starr J; George TJ
Curr Treat Options Oncol; 2017 Nov; 18(12):73. PubMed ID: 29143898
[TBL] [Abstract][Full Text] [Related]
2. Localized Pancreatic Cancer: Multidisciplinary Management.
Coveler AL; Herman JM; Simeone DM; Chiorean EG
Am Soc Clin Oncol Educ Book; 2016; 35():e217-26. PubMed ID: 27249726
[TBL] [Abstract][Full Text] [Related]
3. Treatment of locoregional disease: adjuvant versus neoadjuvant.
Heinemann V
Ann Oncol; 2012 Sep; 23 Suppl 10():x141-7. PubMed ID: 22987951
[TBL] [Abstract][Full Text] [Related]
4. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
5. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).
Tachezy M; Gebauer F; Petersen C; Arnold D; Trepel M; Wegscheider K; Schafhausen P; Bockhorn M; Izbicki JR; Yekebas E
BMC Cancer; 2014 Jun; 14():411. PubMed ID: 24906700
[TBL] [Abstract][Full Text] [Related]
6. Treatment of borderline resectable pancreatic cancer.
Cooper AB; Tzeng CW; Katz MH
Curr Treat Options Oncol; 2013 Sep; 14(3):293-310. PubMed ID: 23793524
[TBL] [Abstract][Full Text] [Related]
7. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
8. Therapy of locally advanced pancreatic adenocarcinoma: unresectable and borderline patients.
Kircher SM; Krantz SB; Nimeiri HS; Mulcahy MF; Munshi HG; Benson AB
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1555-65. PubMed ID: 21999129
[TBL] [Abstract][Full Text] [Related]
9. The role of radiation therapy in pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.
Franke AJ; Rosati LM; Pawlik TM; Kumar R; Herman JM
Semin Oncol; 2015 Feb; 42(1):144-62. PubMed ID: 25726059
[TBL] [Abstract][Full Text] [Related]
10. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation.
Wayne JD; Abdalla EK; Wolff RA; Crane CH; Pisters PW; Evans DB
Oncologist; 2002; 7(1):34-45. PubMed ID: 11854545
[TBL] [Abstract][Full Text] [Related]
11. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
12. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
13. Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment.
Mornex F; Girard N; Delpero JR; Partensky C
Semin Radiat Oncol; 2005 Oct; 15(4):226-34. PubMed ID: 16183476
[TBL] [Abstract][Full Text] [Related]
14. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
[TBL] [Abstract][Full Text] [Related]
16. Multidisciplinary management of resectable adenocarcinoma of the pancreatic head.
Yamamoto M; Imagawa DK; Katz MH
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1611-21. PubMed ID: 18925853
[TBL] [Abstract][Full Text] [Related]
17. Evolving strategies for the treatment of adenocarcinoma of the pancreas. A review.
Ettinghausen SE; Schwartzentruber DJ; Sindelar WF
J Clin Gastroenterol; 1995 Jul; 21(1):48-60. PubMed ID: 7560834
[TBL] [Abstract][Full Text] [Related]
18. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for chemoradiotherapy in the treatment of pancreatic carcinoma?
Pasetto LM; Jirillo A; Stefani M; Monfardini S
Anticancer Res; 2003; 23(3C):2805-13. PubMed ID: 12926117
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
